In the DAPA-HF trial, SGLT-2i dapagliflozin added to optimal standard therapy in patients with HF with reduced ejection fraction, reduced the risk of worsening HF events, CV death, and improved symptoms.
Heart failure, the earliest and most preventable complication of diabetes, and the most treatable – glucose-lowering drugs can affect its progression long before they impact microvascular events.
New guidelines from the EASD and ADA retain metformin as first-line treatment for T2D. Preferred second-line therapies, however, are now SGLT-2i or GLP-1RA, depending on the presence of/risk for CVD and CKD.
Recent evidence of beneficial macrovascular protection from new anti-diabetic drugs has intensified the importance of appropriate strategies to lower glucose in individual diabetes patients.
People with type 2 diabetes (T2d) are at high risk for adverse cardiovascular (cV) outcomes and progressive decline in renal function.
Heart failure and diabetes are closely related, with each conferring a poorer prognosis on the other. Careful consideration of the glycaemic control agent can help prevent incident heart failure.